Vertex Soars on Drug Trial Results
Shares of Vertex Pharmaceutical (VRTX) rose sharply Friday after trials of its experimental hepatitis C treatment showed the drug provided benefit even after therapy stopped. Separately, the company posted a 46-cent loss per share in the third quarter. S&P downgraded the shares to hold from strong buy on valuation.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.